ImmunityBio Grabs BCG Rights Ahead of Make-or-Break FDA Ruling

NEW YORK, May 17 —

ImmunityBio is acquiring U.S. rights to Tokyo strain BCG, ending a 10-year shortage, as an Anktiva FDA ruling looms.

What Actually Happened

BCG (Bacillus Calmette-Guerin), a century-old tuberculosis vaccine adapted as the front-line treatment for non-muscle-invasive bladder cancer, has been in shortage in the U.S. for roughly a decade. Manufacturers exited the market; what remained got rationed. Clinicians stretched vials and delayed treatment cycles. ImmunityBio's deal to bring the Tokyo strain stateside is a genuine supply fix for a genuine clinical problem.

The commercial logic runs deeper than goodwill. Anktiva is designed to be administered in combination with BCG, which means BCG availability is a direct ceiling on Anktiva's commercial potential. By securing U.S. rights to the Tokyo strain, ImmunityBio is building supply infrastructure around its own drug's uptake. That is not altruism. That is a distribution moat, and most sell-side coverage has not connected those two dots.

The Catch

At 75.9x forward P/E on $141mn TTM revenue, this is not a value story. It is a leveraged bet on FDA approval. If the Anktiva ruling comes back negative or delayed, the BCG rights deal becomes a footnote and the multiple collapses. Biotech stocks at stretched valuations that miss binary regulatory events sell off hard. BCG rights alone add nothing to the earnings line.

A positive FDA ruling is not a revenue event — it is a starting gun. Formulary placement takes months. Payers negotiate reimbursement on their own timeline. Physicians in bladder cancer adopt new combination regimens cautiously. The commercial ramp will be slower than the stock price suggests.

Bottom Line

The BCG acquisition is the smarter story here, even if Anktiva is the louder one. ImmunityBio is not just addressing a decade-long clinical gap — it is removing a supply constraint that was a ceiling on its own drug's market penetration. That strategic overlap deserves more credit than the headline writers are giving it. Growth investors who believe Anktiva clears the FDA now face one fewer bottleneck than they did a week ago. Value investors should stay well clear of a 75.9x multiple on the eve of a binary regulatory event.

The one number to watch is the Anktiva PDUFA date. Everything else is noise until then. Run a full ImmunityBio deep-dive at /stock/ibrx to see how the pipeline fits together.

Basis Report does not hold positions in securities discussed. This is not investment advice.